ADDED
The number of outstanding Common Shares of the Registrant as of March 25, 2026 was 8,967,693 .
Risks Related to Our Financial Position and Capital Needs We have incurred losses since inception, we anticipate that we will incur continued losses for the foreseeable future and will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.
There is no active market for our warrants and pre-funded warrants.
The ProMIS platform offers the ability to identify targets (conformational epitopes) unique to the toxic, misfolded form.
Based on current clinical trial patient visit schedules, the Company expects to complete the six-month assessments in the second quarter of 2026, with the blinded interim analysis anticipated in early third quarter 2026.
Completion of dosing and all patient visits is expected in the fourth quarter of 2026, with top-line data anticipated in early 2027 following database lock and statistical analysis.
Strategic Growth and Corporate Visibility: Enhance corporate awareness by engaging strategically with investors and industry stakeholders, while evaluating partnership and business development opportunities that underscore the value of the company's pipeline.
During 2024, it was estimated there were 6.9 million Americans 65 and older living with AD, and that number is projected to rise to 12.7 million by 2050 (www.alz.org, Alzheimer s disease Facts and Figures 2024).
Plasma levels of ptau 217 and ptau 181 (tau protein phosphorylated at amino acids 217 and 181 respectively) correlate with brain imaging measures, AD diagnosis, and disease progression (Mattson et al.
Three mAbs (Aduhelm, Leqembi, Kisunla) were approved from 2021 to 2024, which creates a third category of marketed AD treatments, and the first to be considered disease modifying.
REMOVED
The number of outstanding Common Shares of the Registrant as of March 29, 2025 was 32,689,190 .
Risks Related to Our Financial Position and Capital Needs We have incurred losses since inception, we anticipate that we will incur continued losses for the foreseeable future and there is substantial doubt about our ability to continue as a going concern for the full one-year period following the issuance of the consolidated financial statements.
We will require additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our development programs, commercialization efforts or other operations.
Public Company We are currently not in compliance with Nasdaq s continued listing requirements.
If we are unable to regain compliance with Nasdaq s listing requirements, our Common Shares could be delisted, which could affect the market price of our Common Shares and liquidity and reduce our ability to raise capital.
Our internal controls over financial reporting are not effective, which could have a material and adverse effect on our business.
The ProMIS platform offers the ability to identify targets (epitopes) unique to the toxic, misfolded form.
Strategic Growth and Corporate Visibility: Expand corporate awareness through targeted investor and industry engagement while actively evaluating partnership and business development opportunities to enhance the company's pipeline.
The early symptoms of AD, especially at the inaugural stage of mild cognitive impairment (MCI), are often missed because they are frequently and mistakenly taken for natural signs of ageing.
Plasma levels of p217 tau and p181 tau (tau protein phosphorylated at amino acids 217 and 181 respectively) correlate with brain imaging measures, AD diagnosis, and progression (Mattson et al.